5734-68-9

Usage

Uses

Used in Agricultural Industry:
4,6-Dichloro-N,N-dimethyl-2-pyrimidinamine is used as a fungicide for controlling fungal infections that can damage crops, ensuring a higher yield and better quality of produce.
4,6-Dichloro-N,N-dimethyl-2-pyrimidinamine is also used as a herbicide to manage and eliminate unwanted weeds that compete with crops for nutrients, sunlight, and space, thus supporting efficient crop cultivation.
Used in Household Products:
In some household products, 4,6-Dichloro-N,N-dimethyl-2-pyrimidinamine is used as a pest control agent to manage and eliminate pests that can infest homes and other living spaces, contributing to a cleaner and healthier environment.
Used in Industrial Applications:
4,6-Dichloro-N,N-dimethyl-2-pyrimidinamine is used in industrial settings as a preservative for wood and textile materials, protecting them from fungal and microbial degradation, thereby extending their lifespan and maintaining their quality.
It is crucial to handle 4,6-Dichloro-N,N-dimethyl-2-pyrimidinamine with care due to its potential toxicity, and it should be used strictly in accordance with safety guidelines and regulations to minimize any adverse effects on human health and the environment.

InChI:InChI=1/C6H7Cl2N3/c1-11(2)6-9-4(7)3-5(8)10-6/h3H,1-2H3

Upstream product

• 3764-01-0 2,4,6-trichloropyrimidine 
• 124-40-3 dimethyl amine 
• 117290-56-9 2-dimethylamino-1H-pyrimidine-4,6-dione 
• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 74-88-4 methyl iodide 

Downstream Products

• 13012-26-5 4-chloro-6-methoxy-N,N-dimethylpyrimidin-2-amine 
• 1202-22-8 6-chloro-N₂,N₂,N₄,N₄-tetrapyrimidin-2,4-diamine 
• 1075-39-4 4-Amino-6-chlor-2-dimethylamino-pyrimidin 
• 117077-96-0 (4-benzyloxy-6-chloro-pyrimidin-2-yl)-dimethyl-amine 
• 119222-45-6 4-chloro-2-(N,N-dimethylamino)-6-(2-fluorobenzylamino)-pyrimidine 

Relevant academic research and scientific papers

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

“Doubly Orthogonal” Labeling of Peptides and Proteins

Herein, we report a cysteine bioconjugation methodology for the introduction of hypervalent iodine compounds onto biomolecules. Ethynylbenziodoxolones (EBXs) engage thiols in small organic molecules and cysteine-containing peptides and proteins in a fast and selective addition onto the alkynyl triple bond, resulting in stable vinylbenziodoxolone hypervalent iodine conjugates. The conjugation occurs at room temperature in an open flask under physiological conditions. The use of an azide-bearing EBX reagent enables a “doubly orthogonal” functionalization of the bioconjugate via strain-release-driven cycloaddition and Suzuki-Miyaura cross-coupling of the vinyl hypervalent iodine bond. We successfully applied the methodology on relevant and complex biomolecules, such as histone proteins. Through single-molecule experiments, we illustrated the potential of this doubly reactive bioconjugate by introducing a triplet-state quencher close to a fluorophore, which extended its lifetime by suppressing photobleaching. This work is therefore expected to find broad applications for peptide and protein functionalization. Understanding the molecular basis of life is essential in the search for new medicines. Chemical biology develops molecular tools for studying biological processes, setting the basis for new diagnostics and therapeutics, and relies heavily on the ability to selectively modify biomolecules. Two approaches have been especially fruitful: (1) selective modification of natural biomolecules and (2) selective reaction between non-natural functionalities in the presence of biomolecules (the so-called orthogonal bioconjugation). In our work, we contribute to both by transferring highly reactive hypervalent iodine reagents to cysteine residues in proteins and peptides. The obtained bioconjugates retain the reactive hypervalent bonds, which can be selectively functionalized via a metal-mediated reaction. Combined with a traditional azide tag, our approach allows a doubly orthogonal functionalization of biomolecules and is hence expected to be highly useful in chemical biology. Chemical biology develops molecular tools for studying biological processes, setting the basis for new diagnostics and therapeutics, and relies heavily on the ability to modify selectively biomolecules. In our work, we introduce hypervalent iodine bonds into peptides and proteins, via functionalization of cysteine, by using unique cyclic reagents developed in our group. The hypervalent bond can then be selectively modified in the presence of both natural and synthetic functional groups, opening new opportunities for applications in chemical biology.

HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

Isotopic exchange of hydrogen at C-5 in pyrimidine derivatives: tautomers with an sp3-hybridised C-5 carbon atom

The proton-to-deuterium exchange reaction of the hydrogen atom, at the 5-position of 1.5 pyrimidine derivatives has been studied, The exchange proceeds under both acidic and alkaline conditions, Under acidic conditions, the mechanism involves protonation